DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for placenta accreta — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePlacenta accreta maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for placenta accreta is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
plasminogen (PLG) — PLG is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet bctdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4DUR · 2.45 Å · ligand BICARBONATE ION (BCT). Experimental structure, not a prediction.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
International Journal of Surgery Case Reports · 2024 · 2 citations · open access
Successful conservative surgical management of first-trimester placenta accreta: Case report
AbstractINTRODUCTION AND IMPORTANCE: Placenta accreta spectrum in the first trimester is a rare but life-threatening condition. Its diagnosis and management remain challenging due to the lack of diagnostic criteria and therapeutic guidelines. This case report emphasizes the importance of early diagnosis of first trimester placenta accreta to perform fertility-sparing management. CASE PRESENTATION: A 29-year-old gravida 2 para 1 woman, with history of cesarean delivery, presented with abnormal uterine bleeding. On physical examination, she had minimal vaginal bleeding with normal haemodynamic parameters. An endovaginal ultrasound revealed a non-viable fetus and a low implanted gestational sac. Cesarean scar pregnancy (CSP) was suspected. The patient underwent an ultrasound-guided uterine dilatation and curettage, complicated with massive bleeding. Before an emergency laparotomy was carried out, bleeding was controlled with a Foley catheter balloon. Conservative management was performed with bilateral hypogastric artery ligation followed by the placenta accreta niche resection. Pathology confirmed first-trimester placenta accreta. CLINICAL DISCUSSION: Placenta accreta spectrum disorders can occur even in the first trimester. Traditionally, hysterectomy has been the treatment of choice, but conservative management is possible with careful case selection and monitoring. Careful preoperative planning, including multidisciplinary consultation, is key to improving maternal outcomes. Maintaining high index of suspicion for placenta accreta spectrum disorders, and early diagnosis through ultrasonography, is crucial in the first trimester to perform fertility-sparing surgical management. CONCLUSION: Placenta accreta spectrum incidence is increasingly rising. First-trimester placenta accreta should be suspected in high-risk situations. Conservative management can be offered in selected cases.
Placenta left in situ treatment for placenta accreta
AbstractPlacenta left in situ treatment is one of conservative management of placenta accreta. With the development progress of adjuvant treatment, management of placenta left in situ has been recognized. In this article, we reviewed the placenta left in situ management, adjuvant treatment, indications, contraindications, complications and curative effect.
Key words:
Placenta left in situ; Placenta accreta; Methotrexate; Hysteroscopy; Treatment outcome
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
